FDA
-
-
-
-
-
-
-
Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
-
-
-
-
-
-
-
Journey Medical Corporation to Present at the Emerging Growth Conference
-
-
-
-
-
-
-
Journey Medical Corp (DERM) set to join Russell 2000 and 3000
-
-
-
-
-
-
-
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
-
-
-
-
-
-
-
Journey Medical Corp (DERM) Announces Publication of the Phase 3 Clinical Trial Results of Emrosi
-
-
-
-
-
-
-
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
-
332,104 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

